Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹1,640Prev. Close
₹1,632.8Turnover(Lac.)
₹20,166.85Day's High
₹1,655Day's Low
₹1,62652 Week's High
₹1,72852 Week's Low
₹884.25Book Value
₹454.87Face Value
₹2Mkt Cap (₹ Cr.)
74,341.66P/E
31.96EPS
51.02Divi. Yield
0.49Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 91 | 90.9 | 90.79 | 90.68 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 18,320.86 | 18,059.29 | 18,474.78 | 17,382.52 |
Net Worth | 18,411.86 | 18,150.19 | 18,565.57 | 17,473.2 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 11,771.67 | 11,055.93 | 11,025.66 | 10,080.58 |
yoy growth (%) | 6.47 | 0.27 | 9.37 | -20.16 |
Raw materials | -4,467.26 | -4,182.31 | -4,207.27 | -3,474.35 |
As % of sales | 37.94 | 37.82 | 38.15 | 34.46 |
Employee costs | -1,918.16 | -1,695.86 | -1,703.22 | -1,441.64 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | -161.53 | 1,629.7 | 1,811.46 | 1,793.93 |
Depreciation | -514.19 | -502.83 | -518.75 | -389.81 |
Tax paid | -27.17 | -371.08 | -324.7 | -449.27 |
Working capital | -135.75 | -894.67 | -203.16 | 1,003.92 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 6.47 | 0.27 | 9.37 | -20.16 |
Op profit growth | -89.76 | 7.15 | -8.54 | -53.5 |
EBIT growth | -105.27 | -10.39 | 2.01 | -56.58 |
Net profit growth | -114.99 | 72.99 | -45.89 | -57.19 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 19,656.34 | 16,269.98 | 16,192.79 | 14,926.99 | 15,142.8 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 19,656.34 | 16,269.98 | 16,192.79 | 14,926.99 | 15,142.8 |
Other Operating Income | 354.48 | 371.68 | 212.69 | 235.97 | 231.96 |
Other Income | 120.17 | 73.36 | 142.05 | 137.62 | 617.8 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,522.65 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,557.05 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,477.7 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,098.85 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,484 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
M D Gupta
Managing Director
Nilesh Deshbandhu Gupta.
Director & Chief Executive Off
Vinita Gupta
Company Sec. & Compli. Officer
R V Satam
Independent Director
Jean-Luc Belingard
Executive Director & CFO
Ramesh Swaminathan
Independent Director
Mark D McDade
Independent Director
K B S Anand
Independent Director
Punita Kumar Sinha
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Lupin Ltd
Summary
Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.In the year 2001, Lupin Laboratories Ltd was amalgamated with the company and the name was changed to Lupin Ltd. They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003, the
Read More
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lupin Ltd is ₹74341.66 Cr. as of 03 Jul ‘24
The PE and PB ratios of Lupin Ltd is 31.96 and 3.61 as of 03 Jul ‘24
The 52-week high/low is the highest and lowest price at which a Lupin Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lupin Ltd is ₹884.25 and ₹1728 as of 03 Jul ‘24
Lupin Ltd's CAGR for 5 Years at 16.50%, 3 Years at 12.05%, 1 Year at 82.99%, 6 Month at 17.10%, 3 Month at 1.42% and 1 Month at 3.08%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.